MedTrace Logo

Tailored H. Pylori Eradication Based on Clarithromycin Resistance

NCT03884348 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 431

Last updated 2019-03-21

No results posted yet for this study

Summary

The investigators investigated the point mutations in the 23S rRNA genes of patients infected with clarithromycin-resistant H. pylori and compared the H. pylori eradication rates based on the identified clinically significant point mutations.

Conditions

  • Helicobacter Pylori Infection
  • Antibiotic Resistant Strain

Interventions

DRUG

proton pump inhibitor, amoxicillin, clarithromycin

non-resistant group with treatment of proton pump inhibitor, amoxicillin, clarithromycin

DRUG

proton pump inhibitor, amoxicillin, metronidazole

clarithromycin-resistant group with treatment of proton pump inhibitor, amoxicillin, metronidazole

Sponsors & Collaborators

  • Kangdong Sacred Heart Hospital

    lead OTHER

Principal Investigators

  • Woon Geon Shin · Kangdong Sacred Heart Hospital

Eligibility

Min Age
19 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2018-12-31
Completion
2018-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03884348 on ClinicalTrials.gov